Pulmonx Corp Files 8-K for Material Agreement
Ticker: LUNG · Form: 8-K · Filed: May 23, 2024 · CIK: 1127537
| Field | Detail |
|---|---|
| Company | Pulmonx Corp (LUNG) |
| Form Type | 8-K |
| Filed Date | May 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $113,118.60, $107,329.50, $92,177.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
Pulmonx filed an 8-K today for a material agreement - details to follow.
AI Summary
On May 23, 2024, Pulmonx Corporation filed an 8-K report. The filing primarily concerns the entry into a material definitive agreement and the filing of financial statements and exhibits. Specific details regarding the agreement or financial figures were not provided in the excerpt.
Why It Matters
This filing indicates a significant business event for Pulmonx Corporation, potentially impacting its operations or financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or alter existing ones for a company.
Key Players & Entities
- Pulmonx Corporation (company) — Registrant
- May 23, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement Pulmonx Corporation entered into?
The provided excerpt does not specify the details of the material definitive agreement.
What financial statements and exhibits are being filed with this 8-K?
The excerpt indicates that financial statements and exhibits are being filed, but does not list their specific contents.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated May 23, 2024.
What is Pulmonx Corporation's principal executive office address?
Pulmonx Corporation's principal executive offices are located at 700 Chesapeake Drive, Redwood City, CA 94063.
What is the SEC file number for Pulmonx Corporation?
The SEC file number for Pulmonx Corporation is 001-39562.
Filing Stats: 958 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2024-05-23 16:24:08
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value LUNG The Nasdaq Stock Market
- $113,118.60 — rent for the Existing Premises shall be $113,118.60 per month and will increase by 3.5% eac
- $107,329.50 — rent for the Expansion Premises will be $107,329.50 per month and will increase by 3.5% eac
- $92,177.10 — rent of the Expansion Premises shall be $92,177.10 starting on March 1, 2025, and will inc
Filing Documents
- lung-20240523.htm (8-K) — 32KB
- exhibit101thirdamendmentto.htm (EX-10.1) — 155KB
- exhibit102thirdamendmentto.htm (EX-10.2) — 69KB
- image_0a.jpg (GRAPHIC) — 98KB
- image_1a.jpg (GRAPHIC) — 127KB
- image_2a.jpg (GRAPHIC) — 89KB
- image_3a.jpg (GRAPHIC) — 89KB
- image_4a.jpg (GRAPHIC) — 66KB
- image_5a.jpg (GRAPHIC) — 276KB
- 0001127537-24-000063.txt ( ) — 1440KB
- lung-20240523.xsd (EX-101.SCH) — 2KB
- lung-20240523_lab.xml (EX-101.LAB) — 21KB
- lung-20240523_pre.xml (EX-101.PRE) — 12KB
- lung-20240523_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On May 17, 2024, Pulmonx Corporation (the "Company") entered into that certain Third Amendment to Office Lease (the "Third Amendment to Office Lease") to its existing lease agreement (the "Original Lease" and, as amended by the Third Amendment to Office Lease, the "Lease") with HCP LS Redwood City, LLC (the "Landlord"), whereby the Landlord leases to the Company 24,591 rentable square feet of space (the "Existing Premises") consisting of all of the rentable area of the building located at 700 Chesapeake Drive, Redwood City, California 94063. The Company also entered into that certain Third Amendment to Sublease Agreement (the "Third Amendment to Sublease") to its existing sublease agreement with Genomic Health, Inc. (the "Sublandlord"), whereby the Sublandlord subleases to the Company 25,254 rentable square feet of space (the "Expansion Premises") consisting of all of the rentable area of the building located at 200 and 250 Chesapeake Drive, Redwood City, California 94063. Under the terms of the Third Amendment to Office Lease, the Company and Landlord have agreed to, among other things, (i) expand the Existing Premises to include the Expansion Premises (together with the Existing Premises, hereinafter referred to as the "Leased Premises"), effective as of June 1, 2028 (the "Expansion Premises Commencement Date"), (ii) extend the lease term for the Existing Premises for a period of ten (10) years, from August 1, 2025 (the "Existing Premises Commencement Date") through July 31, 2035, unless sooner terminated as provided in the Lease, and (iii) make certain leasehold improvements to the Leased Premises as set forth in the Third Amendment to Office Lease. Commencing on the Existing Premises Commencement Date, the monthly base rent for the Existing Premises shall be $113,118.60 per month and will increase by 3.5% each year. The term of the Company's lease of the Expansion Premises directly with Landlord will begi
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Third Amendment to Office Lease, by and between Pulmonx Corporation and HCP LS Redwood City, LLC, dated May 17, 2024. 10.2 Third Amendment to Sublease, by and between Pulmonx Corporation and Genomic Health, Inc., dated May 17, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pulmonx Corporation Dated: May 23, 2024 By: /s/ Mehul Joshi Mehul Joshi Chief Financial Officer